Related Experiment Video
Updated: Aug 5, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel
Yasmine Labiad1, Céline Baier1, Michèle Genin2
1Aix Marseille Univ, TAGC/INSERM UMR1090, Parc Scientifique de Luminy, Marseille, France.
Oncology Research
|July 25, 2026
Summary
Researchers identified two distinct molecular subtypes of HIV-associated Diffuse Large B-cell Lymphoma (DLBCL). These findings reveal differences in gene expression and immune pathways, potentially guiding future targeted therapies for this specific patient group.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Diffuse Large B-cell Lymphoma (DLBCL) classification into subtypes like GCB and ABC is established in HIV-negative patients.
- HIV-associated DLBCL may exhibit unique molecular characteristics due to immune dysregulation.
Purpose of the Study:
- To characterize the transcriptomic landscape of HIV-related DLBCL.
- To identify distinct molecular subtypes and deregulated pathways in HIV-associated DLBCL.
- To explore potential theranostic implications of these molecular profiles.
Main Methods:
- Transcriptomic profiling of 12 HIV-positive DLBCL samples using Agilent microarray.
- Unsupervised hierarchical clustering based on gene expression profiles for tumor classification.
- Analysis of gene expression patterns, including TP53, BCL7A, and BCL2, and pathway analysis.
Main Results:
- Two distinct transcriptomic subgroups of HIV-associated DLBCL were identified.
- Cluster I showed overexpression of TP53 and BCL7A, while Cluster II overexpressed BCL2.
- The 'immune system development' pathway was underexpressed in Cluster I compared to Cluster II.
Conclusions:
- HIV-associated DLBCL comprises at least two molecularly distinct subtypes.
- These subtypes are likely influenced by variations in the tumor microenvironment and immune status.
- Transcriptomic profiles offer potential for guiding targeted therapies, warranting further validation and integration with clinical data.
